Evidence guide · UAE
TB-500: the 'healing peptide' with no human trials of its own
TB-500 is one of six peptides in the October 2026 US compounding policy. How it differs from thymosin beta-4, what the FDA found on evidence and safety, and why the recovery claims rest on other molecules.
Review type: research summary. This page summarises published research and product labels, cited below.
TB-500 is one of the six peptides named in the US Department of Health and Human Services (HHS) compounding policy announced in the Federal Register on 30 October 2026, alongside BPC-157, epitalon, KPV, MOTS-c and Semax. It is sold online and through some clinics as an injectable "healing" or "recovery" peptide. A US Food and Drug Administration (FDA) briefing for a July 2026 advisory meeting lists claims made for it online that run from tendon, muscle and ligament repair to hair growth, stamina and immune support.
Short answer: TB-500 is not the same thing as thymosin beta-4, the natural protein it is named after, and the human trials are of the full-length protein, not of TB-500. For TB-500 itself, the FDA's July 2026 review found no clinical trials, no pharmacokinetic studies in people and no published case reports. Animal pharmacokinetic data exist, in horses and rats, but the FDA found no animal studies of acute toxicity, repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity, or carcinogenicity. In the one cell experiment on TB-500 and wound healing that the FDA's conclusions cite, TB-500 had no significant effect. An October 2026 review for orthopaedic surgeons concluded that routine clinical use cannot currently be recommended.
What TB-500 is
Thymosin beta-4 is a 43-amino-acid protein made throughout the body and found in blood, saliva, tears and wound fluid. TB-500 is a synthetic seven-amino-acid fragment of it, amino acids 17 to 23 (LKKTETQ), with an acetyl group added at one end. That short stretch includes the region thymosin beta-4 uses to bind actin, a protein involved in cell shape and movement. According to the FDA briefing, TB-500 appears to have first been made from thymosin beta-4 in 2003, and a veterinary preparation appeared in 2011, marketed to boost performance in equine and greyhound sports.
The FDA notes that several websites call TB-500 a synthetic version of thymosin beta-4 and use the two names interchangeably, but that they are not the same substance. The October 2026 orthopaedic review makes the same point: TB-500 is frequently conflated with full-length thymosin beta-4, with no validated biological or clinical equivalence between them.
What the evidence says
Grades used here: Strong (consistent results from several good-quality human trials), Moderate (good trials, but few or with mixed results), Limited (small or low-quality human studies), Insufficient (too little human research to judge) and Evidence of harm. Animal and cell studies do not count towards a grade.
Injury recovery and wound healing: Insufficient
The only use the FDA evaluated was wound healing, the use named in the original nomination. None of the three papers cited in that nomination gave TB-500 to people, and the FDA's own literature search found no clinical data on TB-500 in humans. Its conclusion: there is a lack of evidence to evaluate TB-500 for wound healing.
The laboratory picture is mixed. In a 2003 mouse study, the non-acetylated version of the fragment, applied to skin wounds in aged mice, significantly increased epidermal closure and collagen at day 7, but the FDA notes that results for that version cannot be directly extrapolated to TB-500. In a 2024 experiment by a Korean doping-control laboratory, TB-500 itself did not speed closure of scratch wounds in cultured fibroblasts, while one of its breakdown products, a five-amino-acid piece, produced a significant effect, which the FDA described as small. The authors suggested that wound-healing activity reported for TB-500 may come from that metabolite rather than the parent peptide.
Since the FDA review, a 2026 Turkish study in 32 male rats with surgically repaired Achilles tendons (eight per group; four tendons per group in each test) reported a higher load to failure and better tissue scores after four weeks of daily intraperitoneal TB-500 than in vehicle-treated controls, with no added benefit from combining it with BPC-157. The authors also called the material synthetic thymosin beta-4 and did not report its sequence. That is one small animal study. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons says direct musculoskeletal evidence for thymosin beta-4 is limited to cell and rodent studies. A 2026 Sports Medicine review says many unapproved peptides show tissue-repair effects in animal models, but that rigorous human safety data are scarce.
The human trials were of thymosin beta-4, not TB-500
Full-length synthetic thymosin beta-4 has been studied in small human trials. None of these studies used TB-500, and none used the injections sold online for injury recovery:
- Healthy volunteers: in a randomised, placebo-controlled study, four groups of 10 healthy adults were assigned intravenous thymosin beta-4 or placebo in a 4:1 ratio, at 42, 140, 420 or 1,260 mg, first as a single dose and then daily for 14 days. Adverse events were infrequent and mild or moderate, with no serious adverse events or dose-limiting toxicity. The authors were exploring a possible use in heart attacks.
- Leg ulcers: a phase 2, placebo-controlled study in 73 people with venous leg ulcers at eight European sites applied thymosin beta-4 to the skin. Safety was comparable to placebo. The authors reported that the 0.03% dose may have the potential to speed healing, and that complete healing within three months occurred in about 25% of patients, especially those with smaller or milder ulcers.
- Dry eye: in a phase 2 trial of thymosin beta-4 eye drops in 72 people with moderate to severe dry eye, neither primary endpoint was significantly different from placebo, although some secondary measures were.
- Corneal damage: a phase 3 trial of the same eye drops in 18 people with neurotrophic keratopathy reported complete healing at four weeks in 6 of 10 treated and 1 of 8 placebo patients, a difference that did not reach statistical significance (p = 0.0656). Two authors are employed by the company developing the drops, and a third by its parent company.
The October 2026 orthopaedic review notes that thymosin beta-4 has broader human experience in eye, skin and heart research, but that these findings cannot establish musculoskeletal efficacy or safety. They say nothing about a seven-amino-acid fragment injected under the skin.
Safety in people: Insufficient
The FDA briefing for its Pharmacy Compounding Advisory Committee, dated 15 May 2026, found no clinical studies or human exposure data for TB-500 by any route, no pharmacokinetic studies in people, and no animal studies of acute toxicity, repeat-dose toxicity, genotoxicity, developmental and reproductive toxicity, or carcinogenicity. A search of the FDA's drug adverse event database (to 26 March 2025) found no reports; for that database, the FDA notes that reporting is voluntary, that it does not receive all adverse event reports, especially for compounded products, and that it cannot make definitive conclusions about safety. A search of its foods and supplements complaint system from 1 January 2004 to 10 March 2025 retrieved two reports about a blended TB-500 and BPC-157 product, neither with a safety assessment. The FDA concluded that the potential safety risks of TB-500 in people are unknown and raised two specific concerns:
- Immune reactions. As a peptide injected under the skin or into muscle, TB-500 may pose a significant risk of immunogenicity, which the FDA says could be amplified by aggregation and peptide-related impurities. It found no clinical studies of immunogenicity or aggregation.
- Quality. The FDA judged neither TB-500 nor its acetate salt well characterised. It cites inconsistent naming, with multiple salts and derivatives sold under the same common name, so a patient could receive a different substance from the one prescribed. A public certificate for the free base covered appearance, identity and peptide purity, but not assay, impurities, aggregates or bacterial endotoxins. The acetate certificate covered an impurities test, but not identity, assay, aggregates or bacterial endotoxins.
Products sold online add a further layer of doubt. The FDA found TB-500 offered as 2 mg, 3 mg, 5 mg, 10 mg and 15 mg powders for reconstitution, labelled for research use only. A 2023 analysis by France's horse-racing laboratory of products sold online as TB500 and TB1000 reported that their contents were not systematically consistent with how those products had been described.
Where it stands with US regulators
TB-500 is not an FDA-approved drug and is not part of any approved product. FDA staff concluded that its poor characterisation, lack of historical use in compounding, absence of any human safety or effectiveness data and immunogenicity concerns weighed against adding it to the list of substances pharmacies may use for compounding under section 503A, and noted that approved treatments for wounds already exist. TB-500 was discussed at the advisory committee meeting on 23 July 2026. On the FDA page about bulk substances that may present significant safety risks in compounding, TB-500 appears under nominations that were withdrawn, not in the current category 2 table; that entry says the FDA has not identified any human exposure data and lacks important information on whether it would cause harm if given to people.
Sport: banned at all times
The 2026 World Anti-Doping Agency Prohibited List names "Thymosin-ß4 and its derivatives e.g. TB-500" in section S2.3, growth factors and growth factor modulators, which is prohibited in and out of competition. Any athlete subject to anti-doping rules who uses TB-500 risks a violation.
Our view
- TB-500 has a plausible story, borrowed from thymosin beta-4, but no human data of its own. The FDA found no study in which it was given to a person.
- The human trials used full-length thymosin beta-4, as eye drops, a skin treatment or an intravenous infusion, and in two of the patient trials the main result was not statistically significant. They do not support injecting a seven-amino-acid fragment for injuries.
- The cell and animal results conflict: TB-500 did nothing to cultured wounds in one experiment, while one rat tendon study reported benefits. Neither tells you what it does in a person.
- Do not inject TB-500 bought online. Products sold under the name have not systematically matched how they were described, and the FDA flagged immune-reaction and quality concerns for injectable forms.
- If you are recovering from an injury, talk to your doctor or a physiotherapist about treatments with human evidence, and ask about clinical trials rather than self-sourcing peptides.
UAE rules
The US policy applies only in the US and does not register or approve any peptide in the UAE. On 29 July 2026 the Dubai Health Authority issued circular CIR-2026-00000107, "Regulations for Handling Peptide Products in Healthcare Facilities", to all health professionals and facilities under its jurisdiction. A clinic offering peptide injections in Dubai should be DHA-licensed and able to explain how it meets that circular. Ask a pharmacist at Bin Sina, Supercare or Medicina before combining any peptide with your other medicines.
FAQ
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-amino-acid protein; TB-500 is a modified seven-amino-acid fragment of it. The FDA treats them as different substances, and results for the full-length protein do not transfer to TB-500.
Is TB-500 a supplement?
No. It is an unapproved peptide drug substance sold mainly as powder for injection. The FDA found no approved TB-500 product in the US, Canada, Australia, the UK or several other European countries, and none authorised for use in the European Union by the European Medicines Agency.
Does TB-500 help tendons heal?
There is no human evidence either way. One 2026 rat study reported better tendon repair, while a 2024 cell experiment found no wound-healing effect from TB-500 itself. No trial has given TB-500 to people with an injury.
Can athletes use TB-500?
No. Thymosin beta-4 and its derivatives, including TB-500, are prohibited at all times on the 2026 WADA Prohibited List.
Sources
These are the documents this page relies on.
- FDA Briefing Document: FDA evaluation of TB-500-related bulk drug substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23 and 24 July 2026US Food and Drug Administration
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeUS Food and Drug Administration
- Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026 (online 27 October 2026)Journal of the American Academy of Orthopaedic Surgeons (PubMed 42937313)
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935Sports Medicine (PubMed 41966639)
- Rahaman KA, Muresan AR, Min H, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024;1235:124033Journal of Chromatography B (PubMed 38382158)
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837Joint Diseases and Related Surgery (PubMed 42542926)
- Delcourt V, Garcia P, Chabot B, et al. TB500/TB1000 and SGF1000: a scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):458-464Drug Testing and Analysis (PubMed 36482504)
- Ruff D, Crockford D, Girardi G, Zhang Y. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229Annals of the New York Academy of Sciences (PubMed 20536472)
- Guarnera G, DeRosa A, Camerini R. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010;1194:207-212Annals of the New York Academy of Sciences (PubMed 20536470)
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877-884Clinical Ophthalmology (PubMed 26056426)
- Sosne G, Kleinman HK, Springs C, et al. 0.1% RGN-259 (thymosin ß4) ophthalmic solution promotes healing and improves comfort in neurotrophic keratopathy patients in a randomized, placebo-controlled, double-masked phase III clinical trial. Int J Mol Sci. 2022;24(1):554International Journal of Molecular Sciences (PubMed 36613994)
- World Anti-Doping Code International Standard: Prohibited List 2026 (section S2.3)World Anti-Doping Agency
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 2026)US Department of Health and Human Services
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, Docket HHS-OASH-2026-0496. Federal Register 91(209):68526-68527, 30 October 2026Federal Register (GovInfo)
- Category 2 of the bulk substances nominated under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (content current as of 22 April 2026)US Food and Drug Administration
- Circular CIR-2026-00000107: Regulations for Handling Peptide Products in Healthcare Facilities, 29 July 2026Dubai Health Authority